» Articles » PMID: 37378426

Joint Analysis of WES and RNA-Seq Identify Signature Genes Related to Metastasis in Prostate Cancer

Overview
Journal J Cell Mol Med
Date 2023 Jun 28
PMID 37378426
Authors
Affiliations
Soon will be listed here.
Abstract

Prostate cancer (PCa) has a certain degree of heritability, and metastasis occurs as cancer progresses. However, its underlying mechanism remains largely unknown. We sequenced four cases of cancer without metastasis, four metastatic cancer, and four benign hyperplasia tissues as controls. A total of 1839 damaging mutations were identified. Pathway analysis, gene clustering, and weighted gene co-expression network analysis were employed to find characteristics associated with metastasis. Chr19 had the most mutation density and 1p36 had the highest mutation frequency across the genome. These mutations occurred in 1630 genes, including the most frequently mutated genes TTN and PLEC, and dozens of metastasis-related genes, such as FOXA1, NCOA1, CD34, and BRCA2. Ras signalling and arachidonic acid metabolism were uniquely enriched in metastatic cancer. Gene programmes 10 and 11 showed the signatures indicating the occurrence of metastasis better. A module (135 genes) was specifically associated with metastasis. Of them, 67.41% reoccurred in program 10, with 26 genes further retained as the signature genes related to PCa metastasis, including AGR3, RAPH1, SOX14, DPEP1, and UBL4A. Our study provides new molecular perspectives on PCa metastasis. The signature genes and pathways could be served as potential therapeutic targets for metastasis or cancer progression.

Citing Articles

Joint analysis of WES and RNA-Seq identify signature genes related to metastasis in prostate cancer.

Xiang C, Li Y, Wang W, Tao H, Liang N, Wu S J Cell Mol Med. 2023; 27(14):1947-1958.

PMID: 37378426 PMC: 10339098. DOI: 10.1111/jcmm.17781.

References
1.
Xing Y, Liu Y, Qi Z, Liu Z, Wang X, Zhang H . LAGE3 promoted cell proliferation, migration, and invasion and inhibited cell apoptosis of hepatocellular carcinoma by facilitating the JNK and ERK signaling pathway. Cell Mol Biol Lett. 2021; 26(1):49. PMC: 8903694. DOI: 10.1186/s11658-021-00295-4. View

2.
Sahu B, Laakso M, Ovaska K, Mirtti T, Lundin J, Rannikko A . Dual role of FoxA1 in androgen receptor binding to chromatin, androgen signalling and prostate cancer. EMBO J. 2011; 30(19):3962-76. PMC: 3209787. DOI: 10.1038/emboj.2011.328. View

3.
Wen Y, Liu Y, Yeh H, Chen W, Jiang K, Lin S . TCF7L1 regulates cytokine response and neuroendocrine differentiation of prostate cancer. Oncogenesis. 2021; 10(11):81. PMC: 8604986. DOI: 10.1038/s41389-021-00371-6. View

4.
Yu Y, Yu G, Tseng G, Cieply K, Nelson J, DeFrances M . Glutathione peroxidase 3, deleted or methylated in prostate cancer, suppresses prostate cancer growth and metastasis. Cancer Res. 2007; 67(17):8043-50. DOI: 10.1158/0008-5472.CAN-07-0648. View

5.
Li H . A statistical framework for SNP calling, mutation discovery, association mapping and population genetical parameter estimation from sequencing data. Bioinformatics. 2011; 27(21):2987-93. PMC: 3198575. DOI: 10.1093/bioinformatics/btr509. View